This suggests that those with advanced insulin resistance have increased CD62P expression and αIIbβ3 activation in the presence of PGI2, implying that PGI2 is less effective at inhibiting the activation of these markers in individuals with advanced insulin resistance. The gene discussed is SELP; the disease is Insulin resistance.